-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

Benzinga·07/20/2026 11:07:22
Listen to the news

Presentation Details:

Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines

Presentation #: 1435eP

Presentation type: e-Poster

Location: e-Poster Area, Hall 25